NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Annovis Bio's Buntanetap Presentation at Parkinson Study Group Meeting
TL;DR
Annovis Bio's buntanetap shows competitive advantage by reversing cognitive decline in Parkinson's patients with amyloid pathology, potentially positioning it as a leading neurodegenerative treatment.
Annovis Bio will present Phase 3 biomarker data showing buntanetap reduces tau biomarkers and reverses cognitive decline in Parkinson's patients with amyloid co-pathology at the December 2025 Parkinson Study Group meeting.
Annovis Bio's therapy improves cognitive outcomes for neurodegenerative disease patients, offering hope for better quality of life and advancing treatment for Alzheimer's and Parkinson's diseases.
Annovis Bio reveals that Parkinson's patients with amyloid pathology experience more severe cognitive decline, but their drug buntanetap reverses this effect while reducing disease-linked tau biomarkers.
Found this article helpful?
Share it with your network and spread the knowledge!
Annovis Bio will present new buntanetap findings at the 2025 Parkinson Study Group Annual Meeting, expanding on Phase 3 Parkinson's biomarker results and debuting a cross-study comparison of all completed trials.
Annovis Bio is a late-stage clinical drug platform company headquartered in Malvern, Pennsylvania, that develops therapies for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
The presentation will show that Parkinson's patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, and that buntanetap also reduces tau biomarkers linked to disease progression.
It offers the most comprehensive view to date of cognitive outcomes across indications and underscores that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the company's strategic path forward.
The meeting will be held December 4-6, 2025 in San Diego.
The findings suggest that buntanetap may provide cognitive benefits for Parkinson's patients, particularly those with amyloid co-pathology, and may help reduce disease progression biomarkers.
You can visit www.annovisbio.com, follow them on LinkedIn, YouTube, and X, or access their newsroom at https://ibn.fm/ANVS.
InvestorWire is a specialized communications platform that provides wire-grade press release syndication and is part of the IBN Dynamic Brand Portfolio, which distributed this announcement.
Curated from InvestorBrandNetwork (IBN)
